Letter to the Editor:  Hepatic multi-omics insights into Jiangtang tiaozhi formula for glycolipid metabolic disorders

doi:10.4239/wjd.118206

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Aug 15, 2026; 17(8): 118206
Published online Aug 15, 2026. doi: 10.4239/wjd.118206

Letter to the Editor: Hepatic multi-omics insights into Jiangtang tiaozhi formula for glycolipid metabolic disorders

Jia-Yu Lin, Jia-Jie Fu, Di-Guang Wen

Jia-Yu Lin, Di-Guang Wen, School of Medical Imaging, Hangzhou Medical College, Hangzhou 310059, Zhejiang Province, China

Jia-Jie Fu, Department of Radiology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

Author contributions: Lin JY and Fu JJ drafted the manuscript; Wen DG designed the study, supervised the project, and critically revised the manuscript; all authors read and approved the final version of the manuscript.

Conflict-of-interest statement: The authors declare that they have no competing interests.

Corresponding author: Di-Guang Wen, School of Medical Imaging, Hangzhou Medical College, No. 8 Yikang Street, Lin’an District, Hangzhou 310059, Zhejiang Province, China. 2018110626@stu.cqmu.edu.cn

Received: December 28, 2025
Revised: January 12, 2026
Accepted: January 21, 2026
Published online: August 15, 2026
Processing time: 221 Days and 19.6 Hours

Core Tip

Core Tip: Diabetic kidney disease (DKD) is a biologically heterogeneous condition, and uniform treatment strategies may not yield equivalent benefits across patients. Recent real-world evidence supports the use of combined sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists as part of a layered therapeutic approach. This commentary highlights the importance of precision patient selection, stage-specific evaluation, and mechanism-informed decision-making to optimize combination therapy. Integrating clinical phenotypes with emerging biological insights may facilitate more individualized and effective management of DKD.